Neurocrine Biosciences INC Form 4 insider transactions

Neurocrine Biosciences Director Stephen Sherwin reported gifting 1,000 shares of common stock effective September 2, 2025.

A Neurocrine Biosciences director exercised stock options and sold an equivalent number of shares for a significant profit under a pre-arranged trading plan.

Neurocrine Biosciences' Chief Scientific Officer, Jude Onyia, gifted 3,116 shares of common stock in a pre-planned transaction.

Neurocrine Biosciences' Chief Regulatory Officer, Ingrid Delaet, exercised stock options and subsequently sold an equal number of shares at a profit under a pre-arranged 10b5-1 trading plan.

Neurocrine Biosciences' Chief Scientific Officer, Jude Onyia, exercised stock options and subsequently sold 59,819 shares of common stock for a profit, as part of a pre-arranged Rule 10b5-1 trading plan.

Neurocrine Biosciences' Chief Scientific Officer, Jude Onyia, exercised stock options and subsequently sold an equivalent number of common shares on July 2, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.

Neurocrine Biosciences' Chief Medical Officer, Sanjay Chandru Keswani, has been granted 12,846 Restricted Stock Units and 70,101 stock options as part of his compensation package.

Kevin Charles Gorman, a Director at Neurocrine Biosciences Inc. (NBIX), sold 9,613 shares of common stock for approximately $1.16 million, executed under a Rule 10b5-1 trading plan.

Director William H. Rastetter reported the acquisition and disposal of Neurocrine Biosciences stock and restricted stock units.

Director Christine Poon reports acquisition and disposal of Neurocrine Biosciences stock and restricted stock units.

Kevin Charles Gorman, a director at Neurocrine Biosciences, acquired 6,610 non-qualified stock options on May 21, 2025, at a price of $0.

Director Shalini Sharp reports acquisition and disposal of Neurocrine Biosciences stock and derivative securities.

Director Stephen Sherwin reports acquisition and disposal of Neurocrine Biosciences stock and restricted stock units.

Director Richard F. Pops reports acquisition and disposal of Neurocrine Biosciences stock and restricted stock units.

Director George J. Morrow reports acquisition and disposal of Neurocrine Biosciences stock and restricted stock units.

Director Gary A. Lyons reports acquisition and disposal of Neurocrine Biosciences stock and derivative securities.

Director Leslie V. Norwalk reports acquisition and disposal of Neurocrine Biosciences stock and derivative securities.

Director Johanna Mercier reports acquisition and disposal of Neurocrine Biosciences stock and restricted stock units.

Julie Cooke, Chief Human Resources Officer at Neurocrine Biosciences, exercised stock options for 6,468 shares of common stock at a price of $61.82 on May 16, 2025.

Director William Rastetter exercised stock options and sold 30,000 shares of Neurocrine Biosciences under a pre-arranged 10b5-1 trading plan.

Chief Human Resources Officer Julie Cooke reports the acquisition and disposal of Neurocrine Biosciences stock and derivative securities, including transactions under 10b5-1 trading plans.

Director Kevin Gorman reports the vesting of Restricted Stock Units (RSUs) and subsequent sale of Neurocrine Biosciences (NBIX) common stock under pre-arranged 10b5-1 trading plans.

Director Stephen Sherwin sold 13,831 shares of Neurocrine Biosciences (NBIX) common stock at an average price of $116.6888 under a pre-arranged 10b5-1 trading plan.

Eiry Roberts, Chief Medical Officer of Neurocrine Biosciences, reports the acquisition and disposition of common stock and derivative securities, including stock options and restricted stock units, through both market sales and vesting events.

Chief Scientific Officer of Neurocrine Biosciences, Jude Onyia, reports acquisition and disposal of common stock and derivative securities, including stock options and restricted stock units, through both market sales and vesting.

Darin Lippoldt, Chief Legal Officer of Neurocrine Biosciences, reports the acquisition and disposal of common stock and derivative securities, including stock options and restricted stock units, through both market sales and vesting events.

CEO Kyle Gano exercised stock options and sold shares of Neurocrine Biosciences (NBIX) common stock under pre-arranged 10b5-1 trading plans.

Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, reports the acquisition and disposal of common stock and restricted stock units.

David W. Boyer, Chief Corporate Affairs Officer of Neurocrine Biosciences, reports the acquisition and disposition of common stock and derivative securities, including stock options and restricted stock units, through both market sales and vesting.

Chief Commercial Officer Eric Benevich of Neurocrine Biosciences reports acquisition and disposal of common stock and derivative securities, including stock options and restricted stock units, under a pre-arranged trading plan.